Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7762 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD7762 monotherapy followed by AZD7762 + gemcitabine |
| Name | Type | Description |
|---|---|---|
| AZD7762 | DRUG | intravenous infusion |
| Gemcitabine | DRUG | weekly intravenous infusion |
Inclusion Criteria: * Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * ECOG performance status of 0 or 1 * Patient and tumor type must be suitable for treatment wi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AZD7762 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development and has been evaluated in a completed clinical trial involving patients with advanced solid malignancies.
AZD7762 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
AZD7762 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
AZD7762 has been studied in one completed Phase 1 clinical trial, identified as NCT00413686. This trial assessed the safety of AZD7762 administered alone and in combination with gemcitabine in patients with advanced solid malignancies.
AZD7762 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not received regulatory approval.